Treatment options for K. pneumoniae, P. aeruginosa and A. baumannii co-resistant to carbapenems, aminoglycosides, polymyxins and tigecycline: an approach based on the mechanisms of resistance to carbapenems

1.

Papst L, Beović B, Pulcini C, Durante-Mangoni E, Rodríguez-Baño J, Kaye KS, et al. Antibiotic treatment of infections caused by carbapenem-resistant Gram-negative bacilli: an international ESCMID cross-sectional survey among infectious diseases specialists practicing in large hospitals. Clin Microbiol Infect. 2018;24:1070–6. https://doi.org/10.1016/j.cmi.2018.01.015.CrossRefPubMed

2.

Piperaki ET, Tzouvelekis LS, Miriagou V, Daikos GL. Carbapenem-resistant Acinetobacter baumannii: in pursuit of an effective treatment. Clin Microbiol Infect. 2019;25:951–7. https://doi.org/10.1016/j.cmi.2019.03.014.CrossRefPubMed

3.

Karakonstantis S, Kritsotakis EI, Gikas A. Pandrug-resistant Gram-negative bacteria: a systematic review of current epidemiology, prognosis and treatment options. J Antimicrob Chemother. 2019;75:271–82. https://doi.org/10.1093/jac/dkz401.CrossRef

4.

Boucher HW, Talbot GH, Bradley JS, Edwards JE, Gilbert D, Rice LB, et al. Bad bugs, no drugs: no ESKAPE! An update from the infectious diseases society of America. Clin Infect Dis. 2009;48:1–12. https://doi.org/10.1086/595011.CrossRefPubMed

5.

Tacconelli E, Carrara E, Savoldi A, Harbarth S, Mendelson M, Monnet DL, et al. Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis. Lancet Infect Dis. 2018;18:318–27. https://doi.org/10.1016/S1473-3099(17)30753-3.CrossRefPubMed

6.

Aghapour Z, Gholizadeh P, Ganbarov K, Bialvaei AZ, Mahmood SS, Tanomand A, et al. Molecular mechanisms related to colistin resistance in Enterobacteriaceae. Infect Drug Resist. 2019;12:965–75. https://doi.org/10.2147/idr.S199844.CrossRefPubMedPubMedCentral

7.

Elyed AG, Zhong LL, Shen C, Yang Y, Doi Y, Tian GB. Colistin and its role in the era of antibiotic resistance: an extended review (2000–2019). Emerg Microbes Infect. 2020;9(1):868–85. https://doi.org/10.1080/22221751.2020.1754133.CrossRef

8.

Karakonstantis S. A systematic review of implications, mechanisms, and stability of in vivo emergent resistance to colistin and tigecycline in Acinetobacter baumannii. J Chemother. 2020. https://doi.org/10.1080/1120009X.2020.1794393.CrossRefPubMed

9.

Karakonstantis S, Saridakis I. Colistin heteroresistance in Acinetobacter spp; systematic review and meta-analysis of the prevalence and discussion of the mechanisms and potential therapeutic implications. Int J Antimicrob Agents. 2020;56:106065. https://doi.org/10.1016/j.ijantimicag.2020.106065.CrossRefPubMed

10.

Castanheira M, Deshpande LM, Woosley LN, Serio AW, Krause KM, Flamm RK. Activity of plazomicin compared with other aminoglycosides against isolates from European and adjacent countries, including Enterobacteriaceae molecularly characterized for aminoglycoside-modifying enzymes and other resistance mechanisms. J Antimicrob Chemother. 2018;73:3346–54. https://doi.org/10.1093/jac/dky344.CrossRefPubMed

11.

Shankar C, Nabarro LEB, Anandan S, Veeraraghavan B. Minocycline and tigecycline: what is their role in the treatment of carbapenem-resistant Gram-negative organisms? Microb Drug Resist. 2017;23:437–46. https://doi.org/10.1089/mdr.2016.0043.CrossRefPubMed

12.

Pournaras S, Koumaki V, Spanakis N, Gennimata V, Tsakris A. Current perspectives on tigecycline resistance in Enterobacteriaceae: susceptibility testing issues and mechanisms of resistance. Int J Antimicrob Agents. 2016;48:11–8. https://doi.org/10.1016/j.ijantimicag.2016.04.017.CrossRefPubMed

13.

Yasmin M, Fouts DE, Jacobs MR, Haydar H, Marshall SH, White R, et al. Monitoring Ceftazidime–avibactam (CAZ-AVI) and Aztreonam (ATM) concentrations in the treatment of a bloodstream infection caused by a multidrug-resistant Enterobacter sp. Carrying both KPC-4 and NDM-1 carbapenemases. Clin Infect Dis. 2019;71:1095–98. https://doi.org/10.1093/cid/ciz1155.CrossRef

14.

Bassetti M, Ariyasu M, Binkowitz B, Nagata TD, Echols RM, Matsunaga Y, et al. Designing a pathogen-focused study to address the high unmet medical need represented by carbapenem-resistant Gram-negative pathogens—the international, multicenter, randomized, open-label, phase 3 CREDIBLE-CR Study. Infect Drug Resist. 2019;12:3607–23. https://doi.org/10.2147/idr.S225553.CrossRefPubMedPubMedCentral

15.

Banerjee R, Humphries R. Clinical and laboratory considerations for the rapid detection of carbapenem-resistant Enterobacteriaceae. Virulence. 2017;8:427–39. https://doi.org/10.1080/21505594.2016.1185577.CrossRefPubMed

16.

Dortet L, Tandé D, de Briel D, Bernabeu S, Lasserre C, Gregorowicz G, et al. MALDI-TOF for the rapid detection of carbapenemase-producing Enterobacteriaceae: comparison of the commercialized MBT STAR^®-Carba IVD Kit with two in-house MALDI-TOF techniques and the RAPIDEC^® CARBA NP. J Antimicrob Chemother. 2018;73:2352–9. https://doi.org/10.1093/jac/dky209.CrossRefPubMed

17.

Gutierrez-Gutierrez B, Salamanca E, de Cueto M, Hsueh PR, Viale P, Pano-Pardo JR, et al. Effect of appropriate combination therapy on mortality of patients with bloodstream infections due to carbapenemase-producing Enterobacteriaceae (INCREMENT): a retrospective cohort study. Lancet Infect Dis. 2017;17:726–34. https://doi.org/10.1016/s1473-3099(17)30228-1.CrossRefPubMed

18.

Zilberberg MD, Nathanson BH, Sulham K, Fan W, Shorr AF. Carbapenem resistance, inappropriate empiric treatment and outcomes among patients hospitalized with Enterobacteriaceae urinary tract infection, pneumonia and sepsis. BMC Infect Dis. 2017;17:279. https://doi.org/10.1186/s12879-017-2383-z.CrossRefPubMedPubMedCentral

19.

Du X, Xu X, Yao J, Deng K, Chen S, Shen Z, et al. Predictors of mortality in patients infected with carbapenem-resistant Acinetobacter baumannii: a systematic review and meta-analysis. Am J Infect Control. 2019;47:1140–5. https://doi.org/10.1016/j.ajic.2019.03.003.CrossRefPubMed

20.

Tamma PD, Simner PJ. Phenotypic detection of carbapenemase-producing organisms from clinical isolates. J Clin Microbiol. 2018. https://doi.org/10.1128/jcm.01140-18.CrossRefPubMedPubMedCentral

21.

Mentasti M, Prime K, Sands K, Khan S, Wootton M. Rapid detection of IMP, NDM, VIM, KPC and OXA-48-like carbapenemases from Enterobacteriales and Gram-negative non-fermenter bacteria by real-time PCR and melt-curve analysis. Eur J Clin Microbiol Infect Dis. 2019;38:2029–36. https://doi.org/10.1007/s10096-019-03637-5.CrossRefPubMed

22.

Hoyos-Mallecot Y, Cabrera-Alvargonzalez JJ, Miranda-Casas C, Rojo-Martin MD, Liebana-Martos C, Navarro-Mari JM. MALDI-TOF MS, a useful instrument for differentiating metallo-beta-lactamases in Enterobacteriaceae and Pseudomonas spp. Lett Appl Microbiol. 2014;58:325–9. https://doi.org/10.1111/lam.12203.CrossRefPubMed

23.

Baeza LL, Pfennigwerth N, Greissl C, Gottig S, Saleh A, Stelzer Y, et al. Comparison of five methods for detection of carbapenemases in Enterobacterales with proposal of a new algorithm. Clin Microbiol Infect. 2019;25(10):1286.e9–e15. https://doi.org/10.1016/j.cmi.2019.03.003.CrossRef

24.

Meier M, Hamprecht A. Systematic comparison of four methods for detection of carbapenemase-producing Enterobacterales directly from blood cultures. J Clin Microbiol. 2019;57(11):e00709–e719. https://doi.org/10.1128/jcm.00709-19.CrossRefPubMedPubMedCentral

25.

Gaibani P, Lombardo D, Foschi C, Re MC, Ambretti S. Evaluation of five carbapenemase detection assays for Enterobacteriaceae harbouring blaKPC variants associated with ceftazidime/avibactam resistance. J Antimicrob Chemother. 2020;75:2010–13. https://doi.org/10.1093/jac/dkaa079.CrossRefPubMed

26.

Galani I, Karaiskos I, Souli M, Papoutsaki V, Galani L, Gkoufa A, et al. Outbreak of KPC-2-producing Klebsiella pneumoniae endowed with Ceftazidime–avibactam resistance mediated through a VEB-1-mutant (VEB-25), Greece, September to October 2019. Euro surveill. 2020;25(3):2000028. https://doi.org/10.2807/1560-7917.ES.2020.25.3.2000028.CrossRefPubMedCentral

27.

Gill CM, Lasko MJ, Asempa TE, Nicolau DP. Evaluation of the EDTA-Modified Carbapenem inactivation method for detecting metallo-β-lactamase-producing Pseudomonas aeruginosa. J Clin Microbiol. 2020;58(6):e02015–e2019. https://doi.org/10.1128/jcm.02015-19.CrossRefPubMed

28.

Eichenberger EM, Thaden JT. Epidemiology and mechanisms of resistance of extensively drug resistant Gram-negative bacteria. Antibiotics (Basel, Switzerland). 2019;8:37. https://doi.org/10.3390/antibiotics8020037.CrossRef

29.

van Duin D, Doi Y. The global epidemiology of carbapenemase-producing Enterobacteriaceae. Virulence Orgo. 2017;8(4):460–9.CrossRef

30.

Grundmann H, Glasner C, Albiger B, Aanensen DM, Tomlinson CT, Andrasevic AT, et al. Occurrence of carbapenemase-producing Klebsiella pneumoniae and Escherichia coli in the European survey of carbapenemase-producing Enterobacteriaceae (EuSCAPE): a prospective, multinational study. Lancet Infect Dis. 2017;17:153–63. https://doi.org/10.1016/s1473-3099(16)30257-2.CrossRefPubMed

31.

Kazmierczak KM, de Jonge BLM, Stone GG, Sahm DF. In vitro activity of ceftazidime/avibactam against isolates of Pseudomonas aeruginosa collected in European countries: INFORM global surveillance 2012–15. J Antimicrob Chemother. 2018;73:2777–811. https://doi.org/10.1093/jac/dky267.CrossRefPubMed

32.

Karampatakis T, Tsergouli K, Politi L, Diamantopoulou G, Iosifidis E, Antachopoulos C, et al. Molecular epidemiology of endemic carbapenem-resistant Gram-negative bacteria in an intensive care unit. Microb Drug Resist. 2019;25:712–6. https://doi.org/10.1089/mdr.2018.0266.CrossRefPubMed

33.

Saharman YR, Pelegrin AC, Karuniawati A, Sedono R, Aditianingsih D, Goessens WHF, et al. Epidemiology and characterisation of carbapenem-non-susceptible Pseudomon asaeruginosa in a large intensive care unit in Jakarta. Indonesia Int J Antimicrob Agents. 2019;54:655–60. https://doi.org/10.1016/j.ijantimicag.2019.08.003.CrossRefPubMed

34.

Galani I, Karaiskos I, Karantani I, Papoutsaki V, Maraki S, Papaioannou V, et al. Epidemiology and resistance phenotypes of carbapenemase-producing Klebsiella pneumoniae in Greece, 2014 to 2016. Eurosurveillance. 2018;23:1700775. https://doi.org/10.2807/1560-7917.ES.2018.23.30.1700775.CrossRefPubMedCentral

35.

Papadimitriou-Olivgeris M, Bartzavali C, Lambropoulou A, Solomou A, Tsiata E, Anastassiou ED, et al. Reversal of carbapenemase-producing Klebsiella pneumoniae epidemiology from blaKPC- to blaVIM-harbouring isolates in a Greek ICU after introduction of ceftazidime/avibactam. J Antimicrob Chemother. 2019;74:2051–4. https://doi.org/10.1093/jac/dkz125.CrossRefPubMed

36.

Munoz-Price LS, Poirel L, Bonomo RA, Schwaber MJ, Daikos GL, Cormican M, et al. Clinical epidemiology of the global expansion of Klebsiella pneumoniae carbapenemases. Lancet Infect Dis. 2013;13:785–96. https://doi.org/10.1016/S1473-3099(13)70190-7.CrossRefPubMedPubMedCentral

37.

Baroud M, Dandache I, Araj GF, Wakim R, Kanj S, Kanafani Z, et al. Underlying mechanisms of carbapenem resistance in extended-spectrum beta-lactamase-producing Klebsiella pneumoniae and Escherichia coli isolates at a tertiary care centre in Lebanon: role of OXA-48 and NDM-1 carbapenemases. Int J Antimicrob Agents. 2013;41:75–9. https://doi.org/10.1016/j.ijantimicag.2012.08.010.CrossRefPubMed

38.

Doumith M, Ellington MJ, Livermore DM, Woodford N. Molecular mechanisms disrupting porin expression in ertapenem-resistant Klebsiella and Enterobacter spp. Clinical isolates from the UK. J Antimicrob Chemother. 2009;63(4):659–67. https://doi.org/10.1093/jac/dkp029.CrossRefPubMed

39.

Pulzova L, Navratilova L, Comor L. Alterations in outer membrane permeability favor drug-resistant phenotype of Klebsiella pneumoniae. Microb Drug Resist. 2017;23:413–20. https://doi.org/10.1089/mdr.2016.0017.CrossRefPubMed

40.

Dupont H, Gaillot O, Goetgheluck A-S, Plassart C, Emond J-P, Lecuru M, et al. Molecular characterization of carbapenem-nonsusceptible Enterobacterial isolates collected during a prospective interregional survey in france and susceptibility to the novel Ceftazidime–avibactam and aztreonam–avibactam combinations. Antimicrob Agents Chemother. 2015;60:215–21. https://doi.org/10.1128/AAC.01559-15.CrossRefPubMedPubMedCentral

41.

Castanheira M, Deshpande LM, Costello A, Davies TA, Jones RN. Epidemiology and carbapenem resistance mechanisms of carbapenem-non-susceptible Pseudomonas aeruginosa collected during 2009–11 in 14 European and Mediterranean countries. J Antimicrob Chemother. 2014;69:1804–14. https://doi.org/10.1093/jac/dku048.CrossRefPubMed

42.

Botelho J, Grosso F, Peixe L. Antibiotic resistance in Pseudomonas aeruginosa–mechanisms, epidemiology and evolution. Drug Resist Updat. 2019;44:100640. https://doi.org/10.1016/j.drup.2019.07.002.CrossRefPubMed

43.

Castanheira M, Mills JC, Farrell DJ, Jones RN. Mutation-driven β-lactam resistance mechanisms among contemporary ceftazidime-nonsusceptible Pseudomonas aeruginosa isolates from U.S. hospitals. Antimicrob Agents Chemother. 2014;58(11):6844–50. https://doi.org/10.1128/aac.03681-14.CrossRefPubMedPubMedCentral

44.

McCracken MG, Adam HJ, Blondeau JM, Walkty AJ, Karlowsky JA, Hoban DJ, et al. Characterization of carbapenem-resistant and XDR Pseudomonas aeruginosa in Canada results of the CANWARD study. J Antimicrob Chemother. 2019;74:iv32–iv38. https://doi.org/10.1093/jac/dkz285.CrossRefPubMed

45.

Galani I, Papoutsaki V, Karantani I, Karaiskos I, Galani L, Adamou P, et al. In vitro activity of ceftolozane/tazobactam alone and in combination with amikacin against MDR/XDR Pseudomonas aeruginosa isolates from Greece. J Antimicrob Chemother. 2020;75:2164–72. https://doi.org/10.1093/jac/dkaa160.CrossRefPubMed

46.

Karlowsky JA, Lob SH, Kazmierczak KM, Hawser SP, Magnet S, Young K, et al. In vitro activity of imipenem/relebactam against Gram-negative ESKAPE pathogens isolated in 17 European countries: 2015 SMART surveillance programme. J Antimicrob Chemother. 2018;73:1872–9. https://doi.org/10.1093/jac/dky107.CrossRefPubMed

47.

Young K, Painter RE, Raghoobar SL, Hairston NN, Racine F, Wisniewski D, et al. In vitro studies evaluating the activity of imipenem in combination with relebactam against Pseudomonas aeruginosa. BMC Microbiol. 2019;19:150. https://doi.org/10.1186/s12866-019-1522-7.CrossRefPubMedPubMedCentral

48.

Wong D, Nielsen TB, Bonomo RA, Pantapalangkoor P, Luna B, Spellberg B. Clinical and pathophysiological overview of acinetobacter infections: a century of challenges. Clin Microbiol Rev. 2017;30:409–47. https://doi.org/10.1128/cmr.00058-16.CrossRefPubMed

49.

Bonnin RA, Nordmann P, Poirel L. Screening and deciphering antibiotic resistance in Acinetobacter baumannii: a state of the art. Expert Rev Anti Infect Ther. 2013;11:571–83. https://doi.org/10.1586/eri.13.38.CrossRefPubMed

50.

Pournaras S, Dafopoulou K, Del Franco M, Zarkotou O, Dimitroulia E, Protonotariou E, et al. Predominance of international clone 2 OXA-23-producing-Acinetobacter baumannii clinical isolates in Greece, 2015: results of a nationwide study. Int J Antimicrob Agents. 2017;49:749–53. https://doi.org/10.1016/j.ijantimicag.2017.01.028.CrossRefPubMed

51.

Hamidian M, Nigro SJ. Emergence, molecular mechanisms and global spread of carbapenem-resistant Acinetobacter baumannii. Microbial genomics. 2019;5:e000306. https://doi.org/10.1099/mgen.0.000306.CrossRefPubMedCentral

52.

Mohd Sazlly Lim S, Sime FB, Roberts JA. Multidrug-resistant Acinetobacter baumannii infections: current evidence on treatment options and the role of pharmacokinetics/pharmacodynamics in dose optimisation. Int J Antimicrob Agents. 2019;53(6):726–45. https://doi.org/10.1016/j.ijantimicag.2019.02.016.CrossRefPubMed

53.

Mushtaq S, Vickers A, Woodford N, Livermore DM. WCK 4234, a novel diazabicyclooctane potentiating carbapenems against Enterobacteriaceae, Pseudomonas and Acinetobacter with class A, C and D β-lactamases. J Antimicrob Chemother. 2017;72:1688–95. https://doi.org/10.1093/jac/dkx035.CrossRefPubMed

54.

Barnes MD, Kumar V, Bethel CR, Moussa SH, O’Donnell J, Rutter JD, et al. Targeting multidrug-resistant Acinetobacter spp: sulbactam and the diazabicyclooctenone β-Lactamase inhibitor ETX2514 as a novel therapeutic agent. MBio. 2019;10:e00159–e219. https://doi.org/10.1128/mBio.00159-19.CrossRefPubMedPubMedCentral

55.

Zhanel GG, Lawrence CK, Adam H, Schweizer F, Zelenitsky S, Zhanel M, et al. Imipenem-relebactam and meropenem-vaborbactam: two novel carbapenem-beta-lactamase inhibitor combinations. Drugs. 2018;78:65–98. https://doi.org/10.1007/s40265-017-0851-9.CrossRefPubMed

56.

Lob SH, Hoban DJ, Sahm DF, Badal RE. Regional differences and trends in antimicrobial susceptibility of Acinetobacter baumannii. Int J Antimicrob Agents. 2016;47:317–23. https://doi.org/10.1016/j.ijantimicag.2016.01.015.CrossRefPubMed

57.

Suetens C, Latour K, Kärki T, Ricchizzi E, Kinross P, Moro ML, et al. Prevalence of healthcare-associated infections, estimated incidence and composite antimicrobial resistance index in acute care hospitals and long-term care facilities: results from two European point prevalence surveys, 2016 to 2017. Euro Surveill. 2018;23:1800516. https://doi.org/10.2807/1560-7917.ES.2018.23.46.1800516.CrossRefPubMedCentral

58.

Karampatakis T, Antachopoulos C, Tsakris A, Roilides E. Molecular epidemiology of carbapenem-resistant Acinetobacter baumannii in Greece: an extended review (2000–2015). Future Microbiol. 2017;12:801–15. https://doi.org/10.2217/fmb-2016-0200.CrossRefPubMed

59.

Karlowsky JA, Kazmierczak KM, Bouchillon SK, de Jonge BLM, Stone GG, Sahm DF. In Vitro activity of Ceftazidime–avibactam against clinical isolates of Enterobacteriaceae and Pseudomonas aeruginosa collected in Latin American countries: results from the INFORM global surveillance program, 2012–2015. Antimicrob Agents Chemother. 2019. https://doi.org/10.1128/aac.01814-18.CrossRefPubMedPubMedCentral

60.

Jayol A, Nordmann P, Poirel L, Dubois V. Ceftazidime/avibactam alone or in combination with aztreonam against colistin-resistant and carbapenemase-producing Klebsiella pneumoniae. J Antimicrob Chemother. 2018;73:542–4. https://doi.org/10.1093/jac/dkx393.CrossRefPubMed

61.

Castanheira M, Huband MD, Mendes RE, Flamm RK. Meropenem-vaborbactam tested against contemporary Gram-negative isolates collected worldwide during 2014, including carbapenem-resistant, KPC-producing, multidrug-resistant, and extensively drug-resistant Enterobacteriaceae. Antimicrob Agents Chemother. 2017;61:e00567–e617. https://doi.org/10.1128/AAC.00567-17.CrossRefPubMedPubMedCentral

62.

Haidar G, Clancy CJ, Chen L, Samanta P, Shields RK, Kreiswirth BN, et al. Identifying spectra of activity and therapeutic niches for Ceftazidime–avibactam and Imipenem-relebactam against carbapenem-resistant Enterobacteriaceae. Antimicrob Agents Chemother. 2017;61:e00642-17. https://doi.org/10.1128/aac.00642-17.CrossRefPubMedPubMedCentral

63.

Winkler ML, Papp-Wallace KM, Bonomo RA. Activity of ceftazidime/avibactam against isogenic strains of Escherichia coli containing KPC and SHV beta-lactamases with single amino acid substitutions in the omega-loop. J Antimicrob Chemother. 2015;70:2279–86. https://doi.org/10.1093/jac/dkv094.CrossRefPubMedPubMedCentral

64.

Livermore DM, Warner M, Jamrozy D, Mushtaq S, Nichols WW, Mustafa N, et al. In vitro selection of Ceftazidime–avibactam resistance in Enterobacteriaceae with KPC-3 carbapenemase. Antimicrob Agents Chemother. 2015;59:5324–30. https://doi.org/10.1128/aac.00678-15.CrossRefPubMedPubMedCentral

65.

Shields RK, Chen L, Cheng S, Chavda KD, Press EG, Snyder A, et al. Emergence of Ceftazidime–avibactam resistance due to plasmid-borne blakpc-3 mutations during treatment of carbapenem-resistant Klebsiella pneumoniae infections. Antimicrob Agents Chemother. 2017;61:e02097-16. https://doi.org/10.1128/aac.02097-16.CrossRefPubMedPubMedCentral

66.

Pogue JM, Bonomo RA, Kaye KS. Ceftazidime/avibactam, meropenem/vaborbactam, or both? clinical and formulary considerations. Clin Infect Dis. 2019;68:519–24. https://doi.org/10.1093/cid/ciy576.CrossRefPubMed

67.

Mueller L, Masseron A, Prod'Hom G, Galperine T, Greub G, Poirel L, et al. Phenotypic, biochemical and genetic analysis of KPC-41, a KPC-3 variant conferring resistance to Ceftazidime–avibactam and exhibiting reduced carbapenemase activity. Antimicrob Agents Chemother. 2019;63:e01111-19. https://doi.org/10.1128/aac.01111-19.CrossRefPubMedPubMedCentral

68.

Haidar G, Clancy CJ, Shields RK, Hao B, Cheng S, Nguyen MH. Mutations in blaKPC-3 that confer Ceftazidime–avibactam resistance encode novel KPC-3 variants that function as extended-spectrum beta-lactamases. Antimicrob Agents Chemother. 2017;61:e02534-16. https://doi.org/10.1128/aac.02534-16.CrossRefPubMedPubMedCentral

69.

Shields RK, Nguyen MH, Press EG, Chen L, Kreiswirth BN, Clancy CJ. In vitro selection of meropenem resistance among Ceftazidime–avibactam-resistant, meropenem-susceptible Klebsiella pneumoniae isolates with variant KPC-3 carbapenemases. Antimicrob Agents Chemother. 2017;61:e00079-17. https://doi.org/10.1128/aac.00079-17.CrossRefPubMedPubMedCentral

70.

Wilson WR, Kline EG, Jones CE, Morder KT, Mettus RT, Doi Y, et al. Effects of KPC variant and porin genotype on the in vitro activity of meropenem-vaborbactam against carbapenem-resistant Enterobacteriaceae. Antimicrob Agents Chemother. 2019;63:e02048–e2118. https://doi.org/10.1128/AAC.02048-18.CrossRefPubMedPubMedCentral

71.

Ackley R, Roshdy D, Meredith J, Minor S, Anderson WE, Capraro GA, et al. Meropenem-vaborbactam versus Ceftazidime–avibactam for treatment of carbapenem-resistant Enterobacteriaceae infections. Antimicrob Agents Chemother. 2020;64:e02313-19. https://doi.org/10.1128/aac.02313-19.CrossRefPubMedPubMedCentral

72.

Oliva A, D'Abramo A, D'Agostino C, Iannetta M, Mascellino MT, Gallinelli C, et al. Synergistic activity and effectiveness of a double-carbapenem regimen in pandrug-resistant Klebsiella pneumoniae bloodstream infections. J Antimicrob Chemother. 2014;69:1718–20. https://doi.org/10.1093/jac/dku027.CrossRefPubMed

73.

Souli M, Karaiskos I, Masgala A, Galani L, Barmpouti E, Giamarellou H. Double-carbapenem combination as salvage therapy for untreatable infections by KPC-2-producing Klebsiella pneumoniae. Eur J Clin Microbiol Infect Dis. 2017;36:1305–15. https://doi.org/10.1007/s10096-017-2936-5.CrossRefPubMed

74.

Emre S, Moroğlu Ç, Yıldırmak T, Şimşek F, Arabacı Ç, Özkaya Ö, et al. Combination antibiotic therapy in pan-resistant klebsiella pneumoniae infection: a report of two cases. Klimik Dergisi. 2018;31:169–72. https://doi.org/10.5152/kd.2018.40.CrossRef

75.

Oliva A, Mascellino MT, Cipolla A, D'Abramo A, De Rosa A, Savinelli S, et al. Therapeutic strategy for pandrug-resistant Klebsiella pneumoniae severe infections: short-course treatment with colistin increases the in vivo and in vitro activity of double carbapenem regimen. Int J Infect Dis. 2015;33:132–4. https://doi.org/10.1016/j.ijid.2015.01.011.CrossRefPubMed

76.

Garcia-Fernandez S, Garcia-Castillo M, Bou G, Calvo J, Cercenado E, Delgado M, et al. Activity of ceftolozane–tazobactam against Pseudomonas aeruginosa and Enterobacterales isolates recovered in intensive care units in Spain: the SUPERIOR multicentre study. Int J Antimicrob Agents. 2019. https://doi.org/10.1016/j.ijantimicag.2019.02.004.CrossRefPubMed

77.

Pfaller MA, Huband MD, Mendes RE, Flamm RK, Castanheira M. In vitro activity of meropenem/vaborbactam and characterisation of carbapenem resistance mechanisms among carbapenem-resistant Enterobacteriaceae from the 2015 meropenem/vaborbactam surveillance programme. Int J Antimicrob Agents. 2018;52:144–50. https://doi.org/10.1016/j.ijantimicag.2018.02.021.CrossRefPubMed

78.

Karaiskos I, Galani I, Souli M, Giamarellou H. Novel beta-lactam-beta-lactamase inhibitor combinations: expectations for the treatment of carbapenem-resistant Gram-negative pathogens. Expert Opin Drug Metab Toxicol. 2019;15:133–49. https://doi.org/10.1080/17425255.2019.1563071.CrossRefPubMed

79.

Kazmierczak KM, Bradford PA, Stone GG, de Jonge BLM, Sahm DF. In Vitro Activity of Ceftazidime–avibactam and aztreonam–avibactam against OXA-48-carrying enterobacteriaceae isolated as part of the international network for optimal resistance monitoring (INFORM) global surveillance program from 2012 to 2015. Antimicrob Agents Chemother. 2018;62:e00592–e618. https://doi.org/10.1128/aac.00592-18.CrossRefPubMedPubMedCentral

80.

Shaw E, Rombauts A, Tubau F, Padulles A, Camara J, Lozano T, et al. Clinical outcomes after combination treatment with ceftazidime/avibactam and aztreonam for NDM-1/OXA-48/CTX-M-15-producing Klebsiella pneumoniae infection. J Antimicrob Chemother. 2018;73:1104–6. https://doi.org/10.1093/jac/dkx496.CrossRefPubMed

81.

Davido B, Fellous L, Lawrence C, Maxime V, Rottman M, Dinh A. Ceftazidime–avibactam and aztreonam, an interesting strategy to overcome beta-lactam resistance conferred by Metallo-beta-Lactamases in Enterobacteriaceae and Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2017;61:e01008–e1017. https://doi.org/10.1128/aac.01008-17.CrossRefPubMedPubMedCentral

82.

Emeraud C, Escaut L, Boucly A, Fortineau N, Bonnin RA, Naas T, et al. Aztreonam plus clavulanate, tazobactam or avibactam for the treatment of metallo-beta-lactamase-producing-Gram negative related infections. Antimicrob Agents Chemother. 2019;63:e00010–19. https://doi.org/10.1128/aac.00010-19.CrossRefPubMedPubMedCentral

83.

Falcone M, Daikos GL, Tiseo G, Bassoulis D, Giordano C, Galfo V, et al. Efficacy of Ceftazidime–avibactam plus aztreonam in patients with bloodstream infections caused by MBL-producing Enterobacterales. Clin Infect Dis. 2020. https://doi.org/10.1093/cid/ciaa586.CrossRefPubMed

84.

Denervaud-Tendon V, Poirel L, Connolly LE, Krause KM, Nordmann P. Plazomicin activity against polymyxin-resistant Enterobacteriaceae, including MCR-1-producing isolates. J Antimicrob Chemother. 2017;72:2787–91. https://doi.org/10.1093/jac/dkx239.CrossRefPubMed

85.

Pages JM, Peslier S, Keating TA, Lavigne JP, Nichols WW. Role of the outer membrane and porins in susceptibility of beta-lactamase-producing Enterobacteriaceae to Ceftazidime–avibactam. Antimicrob Agents Chemother. 2015;60:1349–59. https://doi.org/10.1128/aac.01585-15.CrossRefPubMed

86.

Shields RK, Clancy CJ, Hao B, Chen L, Press EG, Iovine NM, et al. Effects of Klebsiella pneumoniae carbapenemase subtypes, extended-spectrum beta-lactamases, and porin mutations on the in vitro activity of Ceftazidime–avibactam against carbapenem-resistant K pneumoniae. Antimicrob Agents Chemother. 2015;59(9):5793–7. https://doi.org/10.1128/aac.00548-15.CrossRefPubMedPubMedCentral

87.

Castanheira M, Doyle TB, Hubler C, Sader HS, Mendes RE. Ceftazidime–avibactam activity against a challenge set of carbapenem-resistant Enterobacterales: Ompk36 L3 alterations and β-lactamases with ceftazidime hydrolytic activity lead to elevated MIC values. Int J Antimicrob Agents. 2020;56:106011. https://doi.org/10.1016/j.ijantimicag.2020.106011.CrossRefPubMed

88.

Yasmin M, Marshall S, Jacobs M, Rhoads DD, Rojas LJ, Perez F, et al. 610 Meropenem-vaborbactam (MV) In vitro activity against carbapenem-resistant Klebsiella pneumoniae (CRKP) isolates with outer membrane porin gene mutations. Open Forum Infect Dis. 2019. https://doi.org/10.1093/ofid/ofz360.679.CrossRefPubMedCentral

89.

Canver MC, Satlin MJ, Westblade LF, Kreiswirth BN, Chen L, Robertson A, et al. Activity of Imipenem-relebactam and comparator agents against genetically characterized isolates of carbapenem-resistant. Antimicrob Agents Chemother. 2019;63:e00672–e719. https://doi.org/10.1128/aac.00672-19. CrossRefPubMedPubMedCentral

90.

Dulyayangkul P, Douglas EJA, Lastovka F, Avison MB. Resistance to ceftazidime/avibactam plus meropenem/vaborbactam when both are used together achieved in four steps from metallo-β-lactamase negative Klebsiella pneumoniae. Antimicrob Agents Chemother. 2020. https://doi.org/10.1128/aac.00409-20.CrossRefPubMedPubMedCentral

91.

Zhanel GG, Baxter MR, Adam HJ, Sutcliffe J, Karlowsky JA. In vitro activity of eravacycline against 2213 Gram-negative and 2424 Gram-positive bacterial pathogens isolated in Canadian hospital laboratories: CANWARD surveillance study 2014–2015. Diagn Microbiol Infect Dis. 2018;91:55–62. https://doi.org/10.1016/j.diagmicrobio.2017.12.013.CrossRefPubMed

92.

Morrissey I, Olesky M, Hawser S, Lob SH, Karlowsky JA, Corey GR, et al. In vitro activity of eravacycline against Gram-negative bacilli isolated in clinical laboratories worldwide from 2013 to 2017. Antimicrob Agents Chemother. 2020;64:e01699–e1719. https://doi.org/10.1128/AAC.01699-19.CrossRefPubMedPubMedCentral

93.

Pontikis K, Karaiskos I, Bastani S, Dimopoulos G, Kalogirou M, Katsiari M, et al. Outcomes of critically ill intensive care unit patients treated with fosfomycin for infections due to pandrug-resistant and extensively drug-resistant carbapenemase-producing Gram-negative bacteria. Int J Antimicrob Agents. 2014;43:52–9. https://doi.org/10.1016/j.ijantimicag.2013.09.010.CrossRefPubMed

94.

Perdigao Neto LV, Oliveira MS, Martins RCR, Marchi AP, Gaudereto JJ, da Costa L, et al. Fosfomycin in severe infections due to genetically distinct pan-drug-resistant Gram-negative microorganisms: synergy with meropenem. J Antimicrob Chemother. 2019;74:177–81. https://doi.org/10.1093/jac/dky406.CrossRefPubMed

95.

Kaye KS, Rice LB, Dane AL, Stus V, Sagan O, Fedosiuk E, et al. Fosfomycin for Injection (ZTI-01) Versus piperacillin-tazobactam for the treatment of complicated urinary tract infection including acute pyelonephritis: ZEUS, a phase 2/3 randomized trial. Clin Infect Dis. 2019;69:2045–56. https://doi.org/10.1093/cid/ciz181.CrossRefPubMedPubMedCentral

96.

Falagas ME, Athanasaki F, Voulgaris GL, Triarides NA, Vardakas KZ. Resistance to fosfomycin: mechanisms, frequency and clinical consequences. Int J Antimicrob Agents. 2019;53:22–8. https://doi.org/10.1016/j.ijantimicag.2018.09.013.CrossRefPubMed

97.

Brennan-Krohn T, Pironti A, Kirby JE. Synergistic activity of colistin-containing combinations against colistin-resistant Enterobacteriaceae. Antimicrob Agents Chemother. 2018;62:e00873–e918. https://doi.org/10.1128/aac.00873-18.CrossRefPubMedPubMedCentral

98.

MacNair CR, Stokes JM, Carfrae LA, Fiebig-Comyn AA, Coombes BK, Mulvey MR, et al. Overcoming mcr-1 mediated colistin resistance with colistin in combination with other antibiotics. Nature Communications. 2018;9:458. https://doi.org/10.1038/s41467-018-02875-z.CrossRefPubMedPubMedCentral

99.

Erturk Sengel B, Altinkanat Gelmez G, Soyletir G, Korten V. In vitro synergistic activity of fosfomycin in combination with meropenem, amikacin and colistin against OXA-48 and/or NDM-producing Klebsiella pneumoniae. J Chemother. 2020;32:237-43. https://doi.org/10.1080/1120009x.2020.1745501.CrossRefPubMed

100.

Band VI, Hufnagel DA, Jaggavarapu S, Sherman EX, Wozniak JE, Satola SW, et al. Antibiotic combinations that exploit heteroresistance to multiple drugs effectively control infection. Nature Microbiology. 2019;4:1627–35. https://doi.org/10.1038/s41564-019-0480-z.CrossRefPubMedPubMedCentral

101.

Buehrle DJ, Shields RK, Chen L, Hao B, Press EG, Alkrouk A, et al. Evaluation of the in vitro activity of Ceftazidime–avibactam and ceftolozane–tazobactam against meropenem-resistant Pseudomonas aeruginosa isolates. Antimicrob Agents Chemother. 2016;60:3227–311. https://doi.org/10.1128/aac.02969-15.CrossRefPubMedPubMedCentral

102.

Wi YM, Greenwood-Quaintance KE, Schuetz AN, Ko KS, Peck KR, Song J-H, et al. Activity of ceftolozane–tazobactam against carbapenem-resistant, non-carbapenemase-producing Pseudomonas aeruginosa and associated resistance mechanisms. Antimicrob Agents Chemother. 2017;62:e01970–e2017. https://doi.org/10.1128/AAC.01970-17.CrossRefPubMedPubMedCentral

103.

Mirza HC, Hortac E, Kocak AA, Demirkaya MH, Yayla B, Guclu AU, et al. In vitro activity of ceftolozane–tazobactam and Ceftazidime–avibactam against clinical isolates of meropenem-non-susceptible Pseudomonas aeruginosa: a two-center study. J Glob Antimicrob Resist. 2019;20:334-38. https://doi.org/10.1016/j.jgar.2019.09.016.CrossRefPubMed

104.

Grupper M, Sutherland C, Nicolau DP. Multicenter evaluation of Ceftazidime–avibactam and ceftolozane–tazobactam inhibitory activity against meropenem-nonsusceptible Pseudomonas aeruginosa from blood, respiratory tract, and wounds. Antimicrob Agents Chemother. 2017;61:e00875-17. https://doi.org/10.1128/aac.00875-17.CrossRefPubMedPubMedCentral

105.

Sader HS, Mendes RE, Pfaller MA, Shortridge D, Flamm RK, Castanheira M. Antimicrobial activities of aztreonam–avibactam and comparator agents against contemporary (2016) clinical Enterobacteriaceae isolates. Antimicrob Agents Chemother. 2018;62:e01856–e1917. https://doi.org/10.1128/aac.01856-17.CrossRefPubMed

106.

Asempa TE, Nicolau DP, Kuti JL. Carbapenem-nonsusceptible Pseudomonas aeruginosa isolates from intensive care units in the United States: a potential role for new beta-lactam combination agents. J Clin Microbiol. 2019;57:e00535-19. https://doi.org/10.1128/jcm.00535-19.CrossRefPubMedPubMedCentral

107.

Alvarez Lerma F, Munoz Bermudez R, Grau S, Gracia Arnillas MP, Sorli L, Recasens L, et al. Ceftolozane–tazobactam for the treatment of ventilator-associated infections by colistin-resistant Pseudomonas aeruginosa. Rev Esp Quimioter. 2017;30:224–8.PubMed

108.

Fraile-Ribot PA, Cabot G, Mulet X, Perianez L, Martin-Pena ML, Juan C, et al. Mechanisms leading to in vivo ceftolozane/tazobactam resistance development during the treatment of infections caused by MDR Pseudomonas aeruginosa. J Antimicrob Chemother. 2018;73:658–63. https://doi.org/10.1093/jac/dkx424.CrossRefPubMed

109.

Cabot G, Bruchmann S, Mulet X, Zamorano L, Moya B, Juan C, et al. Pseudomonas aeruginosa ceftolozane–tazobactam resistance development requires multiple mutations leading to overexpression and structural modification of AmpC. Antimicrob Agents Chemother. 2014;58:3091–9. https://doi.org/10.1128/aac.02462-13.CrossRefPubMedPubMedCentral

110.

Fraile-Ribot P, Zamorano L, Orellana R, Barrio-Tofino ED, Sanchez-Diener I, Cortes-Lara S, et al. Activity of imipenem/relebactam against a large collection of Pseudomonas aeruginosa clinical isolates and isogenic beta-lactam resistant mutants. Antimicrob Agents Chemother. 2019;64:e02165-19. https://doi.org/10.1128/aac.02165-19.CrossRefPubMedPubMedCentral

111.

Poirel L, Ortiz De La Rosa JM, Kieffer N, Dubois V, Jayol A, Nordmann P. Acquisition of extended-spectrum β-lactamase ges-6 leading to resistance to ceftolozane–tazobactam combination in Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2019;63:e01809-18. https://doi.org/10.1128/aac.01809-18.CrossRefPubMedPubMedCentral

112.

Karlowsky JA, Kazmierczak KM, de Jonge BLM, Hackel MA, Sahm DF, Bradford PA. In vitro activity of aztreonam–avibactam against Enterobacteriaceae and Pseudomonas aeruginosa isolated by clinical laboratories in 40 countries from 2012 to 2015. Antimicrob Agents Chemother. 2017;61:e00472–e517. https://doi.org/10.1128/AAC.00472-17.CrossRefPubMedPubMedCentral

113.

Mikhail S, Singh NB, Kebriaei R, Rice SA, Stamper KC, Castanheira M, et al. Evaluation of the synergy of Ceftazidime–avibactam in combination with meropenem, amikacin, aztreonam, colistin, or fosfomycin against well-characterized multidrug-resistant Klebsiella pneumoniae and Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2019;63:e00779-19. https://doi.org/10.1128/aac.00779-19.CrossRefPubMedPubMedCentral

114.

Yamano Y. In vitro activity of cefiderocol against a broad range of clinically important Gram-negative bacteria. Clin Infect Dis. 2019;69:S544–S551551. https://doi.org/10.1093/cid/ciz827.CrossRefPubMedPubMedCentral

115.

Sato T, Yamawaki K. Cefiderocol: discovery, chemistry, and in vivo profiles of a novel siderophore cephalosporin. Clin Infect Dis. 2019;69:S538–S543543. https://doi.org/10.1093/cid/ciz826.CrossRefPubMedPubMedCentral

116.

Dobias J, Dénervaud-Tendon V, Poirel L, Nordmann P. Activity of the novel siderophore cephalosporin cefiderocol against multidrug-resistant Gram-negative pathogens. Eur J Clin Microbiol Infect Dis. 2017;36:2319–27. https://doi.org/10.1007/s10096-017-3063-z.CrossRefPubMed

117.

Walsh CC, McIntosh MP, Peleg AY, Kirkpatrick CM, Bergen PJ. In vitro pharmacodynamics of fosfomycin against clinical isolates of Pseudomonas aeruginosa. J Antimicrob Chemother. 2015;70:3042–50. https://doi.org/10.1093/jac/dkv221.CrossRefPubMed

118.

Louie A, Maynard M, Duncanson B, Nole J, Vicchiarelli M, Drusano GL. Determination of the dynamically linked indices of fosfomycin for Pseudomonas aeruginosa in the hollow fiber infection model. Antimicrob Agents Chemother. 2018;62:e02627–e2717. https://doi.org/10.1128/AAC.02627-17.CrossRefPubMedPubMedCentral

119.

Abbott IJ, van Gorp E, Wijma RA, Dekker J, Croughs PD, Meletiadis J, et al. Efficacy of single and multiple oral doses of fosfomycin against Pseudomonas aeruginosa urinary tract infections in a dynamic in vitro bladder infection model. J Antimicrob Chemother. 2020;75:1879–88. https://doi.org/10.1093/jac/dkaa127.CrossRefPubMed

120.

Vidaillac C, Benichou L, Duval RE. In vitro synergy of colistin combinations against colistin-resistant Acinetobacter baumannii, Pseudomonas aeruginosa, and Klebsiella pneumoniae isolates. Antimicrob Agents Chemother. 2012;56:4856–61. https://doi.org/10.1128/aac.05996-11.CrossRefPubMedPubMedCentral

121.

Falagas ME, Bliziotis IA, Kasiakou SK, Samonis G, Athanassopoulou P, Michalopoulos A. Outcome of infections due to pandrug-resistant (PDR) Gram-negative bacteria. BMC Infect Dis. 2005;5:24. https://doi.org/10.1186/1471-2334-5-24.CrossRefPubMedPubMedCentral

122.

Cuba GT, Rocha-Santos G, Cayô R, Streling AP, Nodari CS, Gales AC, et al. In vitro synergy of ceftolozane/tazobactam in combination with fosfomycin or aztreonam against MDR Pseudomonas aeruginosa. J Antimicrob Chemother. 2020;75:1874–78. https://doi.org/10.1093/jac/dkaa095.CrossRefPubMed

123.

Avery LM, Sutherland CA, Nicolau DP. Prevalence of in vitro synergistic antibiotic interaction between fosfomycin and nonsusceptible antimicrobials in carbapenem-resistant Pseudomonas aeruginosa. J Med Microbiol. 2019;68:893–7. https://doi.org/10.1099/jmm.0.000984.CrossRefPubMed

124.

Hsueh SC, Lee YJ, Huang YT, Liao CH, Tsuji M, Hsueh PR. In vitro activities of cefiderocol, ceftolozane/tazobactam, ceftazidime/avibactam and other comparative drugs against imipenem-resistant Pseudomonas aeruginosa and Acinetobacter baumannii, and stenotrophomonas maltophilia, all associated with bloodstream infections in Taiwan. J Antimicrob Chemother. 2018;74:380–86. https://doi.org/10.1093/jac/dky425.CrossRef

125.

Zasowski EJ, Rybak JM, Rybak MJ. The β-lactams strike back: Ceftazidime–avibactam. Pharmacotherapy. 2015;35:755–70. https://doi.org/10.1002/phar.1622.CrossRefPubMedPubMedCentral

126.

Biedenbach DJ, Kazmierczak K, Bouchillon SK, Sahm DF, Bradford PA. In Vitro activity of aztreonam–avibactam against a global collection of Gram-negative pathogens from 2012 and 2013. Antimicrob Agents Chemother. 2015;59:4239–48. https://doi.org/10.1128/AAC.00206-15.CrossRefPubMedPubMedCentral

127.

Testa R, Canton R, Giani T, Morosini MI, Nichols WW, Seifert H, et al. In vitro activity of ceftazidime, ceftaroline and aztreonam alone and in combination with avibactam against European Gram-negative and Gram-positive clinical isolates. Int J Antimicrob Agents. 2015;45:641–6. https://doi.org/10.1016/j.ijantimicag.2014.12.033.CrossRefPubMed

128.

Gil-Marques ML, Moreno-Martinez P, Costas C, Pachon J, Blazquez J, McConnell MJ. Peptidoglycan recycling contributes to intrinsic resistance to fosfomycin in Acinetobacter baumannii. J Antimicrob Chemother. 2018;73:2960–8. https://doi.org/10.1093/jac/dky289.CrossRefPubMed

129.

Seifert H, Stefanik D, Olesky M, Higgins PG. In-vitro activity of the novel fluorocycline TP-6076 against carbapenem-resistant Acinetobacter baumannii. Int J Antimicrob Agents. 2019;55:105829. https://doi.org/10.1016/j.ijantimicag.2019.10.010.CrossRefPubMed

130.

Seifert H, Stefanik D, Sutcliffe JA, Higgins PG. In-vitro activity of the novel fluorocycline eravacycline against carbapenem non-susceptible Acinetobacter baumannii. Int J Antimicrob Agents. 2018;51:62–4. https://doi.org/10.1016/j.ijantimicag.2017.06.022.CrossRefPubMed

131.

Nepka M, Perivolioti E, Kraniotaki E, Politi L, Tsakris A, Pournaras S. In vitro bactericidal activity of trimethoprim-sulfamethoxazole alone and in combination with colistin against carbapenem-resistant Acinetobacter baumannii clinical isolates. Antimicrob Agents Chemother. 2016;60:6903–6. https://doi.org/10.1128/aac.01082-16.CrossRefPubMedPubMedCentral

132.

Fragkou PC, Poulakou G, Blizou A, Blizou M, Rapti V, Karageorgopoulos DE, et al. The role of minocycline in the treatment of nosocomial infections caused by multidrug, extensively drug and pandrug resistant Acinetobacter baumannii: a systematic review of clinical evidence. Microorganisms. 2019;7:159. https://doi.org/10.3390/microorganisms7060159.CrossRefPubMedCentral

133.

Tsakris A, Koumaki V, Dokoumetzidis A. Minocycline susceptibility breakpoints for Acinetobacter baumannii: do we need to re-evaluate them? J Antimicrob Chemother. 2019;74:295–7. https://doi.org/10.1093/jac/dky448.CrossRefPubMed

134.

Zayyad H, Eliakim-Raz N, Leibovici L, Paul M. Revival of old antibiotics: needs, the state of evidence and expectations. Int J Antimicrob Agents. 2017;49:536–41. https://doi.org/10.1016/j.ijantimicag.2016.11.021.CrossRefPubMed

135.

Kohira N, Hackel MA, Ishioka Y, Kuroiwa M, Sahm DF, Sato T, et al. Reduced susceptibility mechanism to cefiderocol, a siderophore cephalosporin, among clinical isolates from a global surveillance programme (SIDERO-WT-2014). J Glob Antimicrob Re. 2020;22:738–41. https://doi.org/10.1016/j.jgar.2020.07.009.CrossRef

136.

Falagas ME, Vardakas KZ, Roussos NS. Trimethoprim/sulfamethoxazole for Acinetobacter spp: a review of current microbiological and clinical evidence. Int J Antimicrob Agents. 2015;46(3):231–41. https://doi.org/10.1016/j.ijantimicag.2015.04.002.CrossRefPubMed

137.

Raz-Pasteur A, Liron Y, Amir-Ronen R, Abdelgani S, Ohanyan A, Geffen Y, et al. Trimethoprim-sulfamethoxazole vs. colistin or ampicillin-sulbactam for the treatment of carbapenem-resistant Acinetobacter baumannii: a retrospective matched cohort study. J Glob Antimicrob Resist. 2019;17:168–72. https://doi.org/10.1016/j.jgar.2018.12.001.CrossRefPubMed

138.

Chen H, Liu Q, Chen Z, Li C. Efficacy of sulbactam for the treatment of Acinetobacter baumannii complex infection: a systematic review and meta-analysis. J Infect Chemother. 2017;23:278–85. https://doi.org/10.1016/j.jiac.2017.01.005.CrossRefPubMed

139.

Cai Y, Chai D, Wang R, Liang B, Bai N. Colistin resistance of Acinetobacter baumannii: clinical reports, mechanisms and antimicrobial strategies. J Antimicrob Chemother. 2012;67:1607–15. https://doi.org/10.1093/jac/dks084.CrossRefPubMed

140.

Nutman A, Lellouche J, Temkin E, Daikos G, Skiada A, Durante-Mangoni E, et al. Colistin plus meropenem for carbapenem-resistant Gram-negative infections: in vitro synergism is not associated with better clinical outcomes. Clin Microbiol Infect. 2020;26:1185-91. https://doi.org/10.1016/j.cmi.2020.03.035.CrossRefPubMed

141.

Perez F, El Chakhtoura NG, Yasmin M, Bonomo RA. Polymyxins: to combine or not to combine? Antibiotics (Basel). 2019;8:38. https://doi.org/10.3390/antibiotics8020038.CrossRef

142.

Durante-Mangoni E, Signoriello G, Andini R, Mattei A, De Cristoforo M, Murino P, et al. Colistin and rifampicin compared with colistin alone for the treatment of serious infections due to extensively drug-resistant Acinetobacter baumannii: a multicenter. Randomized Clinical Trial Clin Infect Dis. 2013;57:349–58. https://doi.org/10.1093/cid/cit253.CrossRefPubMed

143.

Sirijatuphat R, Thamlikitkul V. Preliminary study of colistin versus colistin plus fosfomycin for treatment of carbapenem-resistant Acinetobacter baumannii infections. Antimicrob Agents Chemother. 2014;58:5598–601. https://doi.org/10.1128/aac.02435-13.CrossRefPubMedPubMedCentral

144.

Aranzana-Climent V, Buyck JM, Smani Y, Pachón-Diaz J, Marchand S, Couet W, et al. Semi-mechanistic PK/PD modelling of combined polymyxin B and minocycline against a polymyxin-resistant strain of Acinetobacter baumannii. Clin Microbiol Infect. 2020;26:1254. https://doi.org/10.1016/j.cmi.2020.01.017.CrossRefPubMed

145.

Karakonstantis S, et al. Re: ‘colistin plus meropenem for carbapenem-resistant Gram-negative infections in vitro synergism is not associated with better clinical outcomes’ by Nutman. Clin Microbiol Infect. 2020;26:1274. https://doi.org/10.1016/j.cmi.2020.04.043.CrossRefPubMed

146.

Tsuji BT, Pogue JM, Zavascki AP, Paul M, Daikos GL, Forrest A, et al. International consensus guidelines for the optimal use of the polymyxins: endorsed by the American college of clinical pharmacy (ACCP), European society of clinical microbiology and infectious diseases (ESCMID), infectious diseases society of America (IDSA), international society for anti-infective pharmacology (ISAP), Society of critical care medicine (SCCM), and Society of infectious diseases pharmacists (SIDP). Pharmacotherapy. 2019;39:10–39. https://doi.org/10.1002/phar.2209.CrossRefPubMedPubMedCentral

147.

Nation RL, Velkov T, Li J. Colistin and polymyxin B: peas in a pod, or chalk and cheese? Clin Infect Dis. 2014;59:88–94. https://doi.org/10.1093/cid/ciu213.CrossRefPubMedPubMedCentral

148.

Cai Y, Lee W, Kwa AL. Polymyxin B versus colistin: an update. Expert Rev Anti Infect Ther. 2015;13:1481–97. https://doi.org/10.1586/14787210.2015.1093933.CrossRefPubMed

149.

Zavascki AP, Nation RL. Nephrotoxicity of polymyxins: is there any difference between colistimethate and polymyxin B? Antimicrob Agents Chemother. 2017. https://doi.org/10.1128/aac.02319-16.CrossRefPubMedPubMedCentral

150.

Bae S, Kim M-C, Park S-J, Kim HS, Sung H, Kim M-N, et al. In Vitro synergistic activity of antimicrobial agents in combination against clinical isolates of colistin-resistant Acinetobacter baumannii. Antimicrob Agents Chemother. 2016;60:6774–9. https://doi.org/10.1128/AAC.00839-16.CrossRefPubMedPubMedCentral

151.

Lenhard JR, Thamlikitkul V, Silveira FP, Garonzik SM, Tao X, Forrest A, et al. Polymyxin-resistant, carbapenem-resistant Acinetobacter baumannii is eradicated by a triple combination of agents that lack individual activity. J Antimicrob Chemother. 2017;72:1415–20. https://doi.org/10.1093/jac/dkx002.CrossRefPubMedPubMedCentral

152.

Poulakou G, Renieris G, Sabrakos L, Zarkotou O, Themeli-Digalaki K, Perivolioti E, et al. Daptomycin as adjunctive treatment for experimental infection by Acinetobacter baumannii with resistance to colistin. Int J Antimicrob Agents. 2018. https://doi.org/10.1016/j.ijantimicag.2018.10.024.CrossRefPubMed

153.

Assimakopoulos SF, Karamouzos V, Lefkaditi A, Sklavou C, Kolonitsiou F, Christofidou M, et al. Triple combination therapy with high-dose ampicillin/sulbactam, high-dose tigecycline and colistin in the treatment of ventilator-associated pneumonia caused by pan-drug resistant Acinetobacter baumannii: a case series study. Infez Med. 2019;27:11–6.PubMed

154.

Park HJ, Cho JH, Kim HJ, Han SH, Jeong SH, Byun MK. Colistin monotherapy versus colistin/rifampicin combination therapy in pneumonia caused by colistin-resistant Acinetobacter baumannii: a randomised controlled trial. J Glob Antimicrob Resist. 2019;17:66–71. https://doi.org/10.1016/j.jgar.2018.11.016.CrossRefPubMed

155.

Lertsrisatit Y, Santimaleeworagun W, Thunyaharn S, Traipattanakul J. In vitro activity of colistin mono- and combination therapy against colistin-resistant Acinetobacter baumannii, mechanism of resistance, and clinical outcomes of patients infected with colistin-resistant A. baumannii at a Thai university hospital. Infect Drug Resist. 2017;10:437–43. https://doi.org/10.2147/idr.S148185.CrossRefPubMedPubMedCentral

156.

Rodríguez CH, Barberis C, Nastro M, Bombicino K, Granados G, Vay C, et al. Impact of heteroresistance to colistin in meningitis caused by Acinetobacter baumannii. J Infect. 2012;64:119–21. https://doi.org/10.1016/j.jinf.2011.10.007.CrossRefPubMed

157.

Rodriguez CH, Bombicino K, Granados G, Nastro M, Vay C, Famiglietti A. Selection of colistin-resistant Acinetobacter baumannii isolates in postneurosurgical meningitis in an intensive care unit with high presence of heteroresistance to colistin. Diagn Microbiol Infect Dis. 2009;65:188–91. https://doi.org/10.1016/j.diagmicrobio.2009.05.019.CrossRefPubMed

158.

Kofteridis DP, Andrianaki AM, Maraki S, Mathioudaki A, Plataki M, Alexopoulou C, et al. Treatment pattern, prognostic factors, and outcome in patients with infection due to pan-drug-resistant Gram-negative bacteria. Eur J Clin Microbiol Infect Dis. 2020;39:965–70. https://doi.org/10.1007/s10096-019-03784-9.CrossRefPubMed

159.

Leite GC, Oliveira MS, Perdigao-Neto LV, Rocha CK, Guimaraes T, Rizek C, et al. Antimicrobial combinations against pan-resistant Acinetobacter baumannii isolates with different resistance mechanisms. PLoS ONE. 2016;11:e0151270. https://doi.org/10.1371/journal.pone.0151270.CrossRefPubMedPubMedCentral

160.

Lenhard JR, Smith NM, Bulman ZP, Tao X, Thamlikitkul V, Shin BS, et al. High-dose ampicillin-sulbactam combinations combat polymyxin-resistant Acinetobacter baumannii in a hollow-fiber infection model. Antimicrob Agents Chemother. 2017;61:e01268–e1316. https://doi.org/10.1128/aac.01268-16.CrossRefPubMedPubMedCentral

161.

Qureshi ZA, Hittle LE, O'Hara JA, Rivera JI, Syed A, Shields RK, et al. Colistin-resistant Acinetobacter baumannii: beyond carbapenem resistance. Clin Infect Dis. 2015;60:1295–303. https://doi.org/10.1093/cid/civ048.CrossRefPubMedPubMedCentral

162.

Rodriguez CH, Brune A, Nastro M, Vay C, Famiglietti A. In vitro synergistic activity of the sulbactam/avibactam combination against extensively drug-resistant Acinetobacter baumannii. J Med Microbiol. 2020;69:928-31. https://doi.org/10.1099/jmm.0.001211.CrossRefPubMed

163.

Li J, Yang X, Chen L, Duan X, Jiang Z. In Vitro activity of various antibiotics in combination with tigecycline against Acinetobacter baumannii: a systematic review and meta-analysis. Microb Drug Resist. 2017;23:982–93. https://doi.org/10.1089/mdr.2016.0279.CrossRefPubMed

164.

Elsayed E, Elarabi MA, Sherif DA, Elmorshedi M, El-Mashad N. Extensive drug resistant Acinetobacter baumannii: a comparative study between non-colistin based combinations. Int J Clin Pharm. 2020;42:80–8. https://doi.org/10.1007/s11096-019-00940-1.CrossRefPubMed

165.

Lanini S, Ioannidis JPA, Vairo F, Pletschette M, Portella G, Di Bari V, et al. Non-inferiority versus superiority trial design for new antibiotics in an era of high antimicrobial resistance: the case for post-marketing, adaptive randomised controlled trials. Lancet Infect Dis. 2019;19:e444–e45151. https://doi.org/10.1016/S1473-3099(19)30284-1.CrossRefPubMed

166.

Li YY, Wang J, Wang R, Cai Y. Double-carbapenem therapy in the treatment of multidrug resistant Gram-negative bacterial infections: a systematic review and meta-analysis. BMC Infect Dis. 2020;20:408. https://doi.org/10.1186/s12879-020-05133-0.CrossRefPubMedPubMedCentral

167.

Shields RK, Nguyen MH, Chen L, Press EG, Potoski BA, Marini RV, et al. Ceftazidime–avibactam is superior to other treatment regimens against carbapenem-resistant Klebsiella pneumoniae Bacteremia. Antimicrob Agents Chemother. 2017;61:e00883-17. https://doi.org/10.1128/aac.00883-17.CrossRefPubMedPubMedCentral

168.

Falcone M, Bassetti M, Tiseo G, Giordano C, Nencini E, Russo A, et al. Time to appropriate antibiotic therapy is a predictor of outcome in patients with bloodstream infection caused by KPC-producing Klebsiella pneumoniae. Crit Care. 2020;24:29. https://doi.org/10.1186/s13054-020-2742-9.CrossRefPubMedPubMedCentral

169.

van Duin D, Lok JJ, Earley M, Cober E, Richter SS, Perez F, et al. Colistin versus Ceftazidime–avibactam in the treatment of infections due to carbapenem-resistant Enterobacteriaceae. Clin Infect Dis. 2018;66:163–71. https://doi.org/10.1093/cid/cix783.CrossRefPubMed

170.

Fiore M, Alfieri A, Di Franco S, Pace MC, Simeon V, Ingoglia G, et al. Ceftazidime–avibactam combination therapy compared to Ceftazidime–avibactam monotherapy for the treatment of severe infections due to carbapenem-resistant pathogens: a systematic review and network meta-analysis. Antibiotics (Basel). 2020;9:388. https://doi.org/10.3390/antibiotics9070388.CrossRef

171.

Bassetti M, Giacobbe DR, Patel N, Tillotson G, Massey J. Efficacy and safety of meropenem-vaborbactam versus best available therapy for the treatment of carbapenem-resistant Enterobacteriaceae infections in patients without prior antimicrobial failure: a post hoc analysis. Adv Ther. 2019;36:1771–7. https://doi.org/10.1007/s12325-019-00981-y.CrossRefPubMedPubMedCentral

172.

Kaye KS, Boucher HW, Brown ML, Aggrey A, Khan I, Joeng HK, et al. Comparison of treatment outcomes between analysis populations in the RESTORE-IMI 1 Phase 3 trial of imipenem-cilastatin-relebactam versus colistin plus imipenem-cilastatin in patients with imipenem-nonsusceptible bacterial infections. Antimicrob Agents Chemother. 2020;64:e02203-19. https://doi.org/10.1128/aac.02203-19.CrossRefPubMedPubMedCentral

173.

Tumbarello M, Trecarichi EM, Corona A, De Rosa FG, Bassetti M, Mussini C, et al. Efficacy of Ceftazidime–avibactam salvage therapy in patients with infections Caused by Klebsiella pneumoniae carbapenemase–producing K. pneumoniae. Clin Infect Dis. 2018;68(3):355–64. https://doi.org/10.1093/cid/ciy492.CrossRef

174.

Onorato L, Di Caprio G, Signoriello S, Coppola N. Efficacy of ceftazidime/avibactam in monotherapy or combination therapy against carbapenem-resistant Gram-negative bacteria: a meta-analysis. Int J Antimicrob Agents. 2019;54:735–40. https://doi.org/10.1016/j.ijantimicag.2019.08.025.CrossRefPubMed

175.

McKinnell JA, Dwyer JP, Talbot GH, Connolly LE, Friedland I, Smith A, et al. Plazomicin for infections caused by carbapenem-resistant Enterobacteriaceae. N Engl J Med. 2019;380:791–3. https://doi.org/10.1056/NEJMc1807634.CrossRefPubMed

176.

Alosaimy S, Molina KC, Claeys KC, Andrade J, Truong J, King MA, et al. Early experience with eravacycline for complicated infections. Open Forum Infect Dis. 2020;7(5):ofaa071. https://doi.org/10.1093/ofid/ofaa071.CrossRefPubMedPubMedCentral

177.

Alosaimy S, Abdul-Mutakabbir JC, Kebriaei R, Jorgensen SCJ, Rybak MJ. Evaluation of eravacycline: a novel fluorocycline. Pharmacotherapy. 2020;40:221–38. https://doi.org/10.1002/phar.2366.CrossRefPubMed

178.

Chan JD, Graves JA, Dellit TH. Antimicrobial treatment and clinical outcomes of carbapenem-resistant Acinetobacter baumannii ventilator-associated pneumonia. J Intensive Care Med. 2010;25:343–8. https://doi.org/10.1177/0885066610377975.CrossRefPubMed

179.

Shields RK. Case commentary: the need for Cefiderocol is clear, but are the supporting clinical data? Antimicrob Agents Chemother. 2020;64:e00059-20. https://doi.org/10.1128/aac.00059-20.CrossRefPubMedPubMedCentral

180.

Das S, Li J, Riccobene T, Carrothers TJ, Newell P, Melnick D, et al. Dose selection and validation for Ceftazidime–avibactam in adults with complicated intra-abdominal infections, complicated urinary tract infections, and Nosocomial Pneumonia. Antimicrob Agents Chemother. 2019;63:e02187–e2218. https://doi.org/10.1128/AAC.02187-18.CrossRefPubMedPubMedCentral

181.

Das S, Zhou D, Nichols WW, Townsend A, Newell P, Li J. Selecting the dosage of Ceftazidime–avibactam in the perfect storm of nosocomial pneumonia. Eur J Clin Pharmacol. 2020;76:349–61. https://doi.org/10.1007/s00228-019-02804-z.CrossRefPubMed

182.

Bensman TJ, Wang J, Jayne J, Fukushima L, Rao AP, D'Argenio DZ, et al. Pharmacokinetic-Pharmacodynamic target attainment analyses to determine optimal dosing of Ceftazidime–avibactam for the treatment of acute pulmonary exacerbations in patients with cystic fibrosis. Antimicrob Agents Chemother. 2017;61:e00988–e1017. https://doi.org/10.1128/aac.00988-17.CrossRefPubMedPubMedCentral

183.

Lodise TP, Smith NM, O'Donnell N, Eakin AE, Holden PN, Boissonneault KR, et al. Determining the optimal dosing of a novel combination regimen of ceftazidime/avibactam with aztreonam against NDM-1-producing Enterobacteriaceae using a hollow-fibre infection model. J Antimicrob Chemother. 2020;75:2622–32. https://doi.org/10.1093/jac/dkaa197.CrossRefPubMed

184.

Layeux B, Taccone FS, Fagnoul D, Vincent JL, Jacobs F. Amikacin monotherapy for sepsis caused by panresistant Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2010;54:4939–41. https://doi.org/10.1128/aac.00441-10.CrossRefPubMedPubMedCentral

185.

Drusano GL, Ambrose PG, Bhavnani SM, Bertino JS, Nafziger AN, Louie A. Back to the future: using aminoglycosides again and how to dose them optimally. Clin Infect Dis. 2007;45:753–60. https://doi.org/10.1086/520991.CrossRefPubMed

186.

Pouzot-Nevoret C, Magnin M, Ayoub JY, Bourguignon L, Maire P, Wertz D, et al. Evaluation of haemodialysis as a protective technique for preventing high daily dose amikacin nephrotoxicity: an experimental study in an ovine model. Int J Antimicrob Agents. 2017;50:148–54. https://doi.org/10.1016/j.ijantimicag.2017.03.029.CrossRefPubMed

187.

Brasseur A, Hites M, Roisin S, Cotton F, Vincent JL, De Backer D, et al. A high-dose aminoglycoside regimen combined with renal replacement therapy for the treatment of MDR pathogens: a proof-of-concept study. J Antimicrob Chemother. 2016;71:1386–94. https://doi.org/10.1093/jac/dkv491.CrossRefPubMed

188.

Song X, Wu Y, Cao L, Yao D, Long M. Is meropenem as a monotherapy truly incompetent for meropenem-nonsusceptible bacterial strains? a pharmacokinetic/pharmacodynamic modeling with monte carlo simulation. Front Microbiol. 2019;10:2777. https://doi.org/10.3389/fmicb.2019.02777.CrossRefPubMedPubMedCentral

189.

Natesan S, Pai MP, Lodise TP. Determination of alternative ceftolozane/tazobactam dosing regimens for patients with infections due to Pseudomonas aeruginosa with MIC values between 4 and 32 mg/L. J Antimicrob Chemother. 2017;72:2813–6. https://doi.org/10.1093/jac/dkx221.CrossRefPubMed

190.

Jaruratanasirikul S, Wongpoowarak W, Wattanavijitkul T, Sukarnjanaset W, Samaeng M, Nawakitrangsan M, et al. Population pharmacokinetics and pharmacodynamics modeling to optimize dosage regimens of sulbactam in critically ill patients with severe sepsis caused by Acinetobacter baumannii. Antimicrob Agents Chemother. 2016;60:7236–44. https://doi.org/10.1128/aac.01669-16.CrossRefPubMedPubMedCentral

191.

Jaruratanasirikul S, Nitchot W, Wongpoowarak W, Samaeng M, Nawakitrangsan M. Population pharmacokinetics and monte carlo simulations of sulbactam to optimize dosage regimens in patients with ventilator-associated pneumonia caused by Acinetobacter baumannii. Eur J Pharm Sci. 2019;136:104940. https://doi.org/10.1016/j.ejps.2019.05.018.CrossRefPubMed

192.

Asuphon O, Montakantikul P, Houngsaitong J, Kiratisin P, Sonthisombat P. Optimizing intravenous fosfomycin dosing in combination with carbapenems for treatment of Pseudomonas aeruginosa infections in critically ill patients based on pharmacokinetic/pharmacodynamic (PK/PD) simulation. Int J Infect Dis. 2016;50:23–9. https://doi.org/10.1016/j.ijid.2016.06.017.CrossRefPubMed

193.

Abbott IJ, van Gorp E, Wijma RA, Meletiadis J, Roberts JA, Mouton JW, et al. Oral Fosfomycin efficacy with variable urinary exposures following single and multiple doses against Enterobacterales: the importance of heteroresistance for growth outcome. Antimicrob Agents Chemother. 2020;64:e01982-19. https://doi.org/10.1128/aac.01982-19.CrossRefPubMedPubMedCentral

194.

Abbott IJ, Dekker J, van Gorp E, Wijma RA, Raaphorst MN, Klaassen CHW, et al. Impact of bacterial species and baseline resistance on fosfomycin efficacy in urinary tract infections. J Antimicrob Chemother. 2020;75:988–96. https://doi.org/10.1093/jac/dkz519.CrossRefPubMed

195.

Molinaro M, Morelli P, De Gregori M, De Gregori S, Giardini I, Tordato F, et al. Efficacy of intraventricular amikacin treatment in pan-resistant Pseudomonas aeruginosa postsurgical meningitis. Infect Drug Resist. 2018;11:1369–72. https://doi.org/10.2147/idr.S169271.CrossRefPubMedPubMedCentral

196.

Nau R, Blei C, Eiffert H. Intrathecal antibacterial and antifungal therapies. Clin Microbiol Rev. 2020;33:e00190-19. https://doi.org/10.1128/cmr.00190-19.CrossRefPubMed

197.

Giua R, Pedone C, Cortese L, Antonelli IR. Colistin bladder instillation, an alternative way of treating multi-resistant Acinetobacter urinary tract infection: a case series and review of literature. Infection. 2014;42:199–202. https://doi.org/10.1007/s15010-013-0507-y.CrossRefPubMed

198.

Pietropaolo A, Jones P, Moors M, Birch B, Somani BK. Use and effectiveness of antimicrobial intravesical treatment for Prophylaxis and treatment of recurrent urinary tract infections (UTIs): a systematic review. Curr Urol Rep. 2018;19:78. https://doi.org/10.1007/s11934-018-0834-8.CrossRefPubMedPubMedCentral

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Treatment options for K. pneumoniae, P. aeruginosa and A. baumannii co-resistant to carbapenems, aminoglycosides, polymyxins and tigecycline: an approach based on the mechanisms of resistance to carbapenems

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 6/2020

Detection of HIV-1 viral load in tears of HIV/AIDS patients

Spatial distribution and incidence trend of human alveolar echinococcosis in southwest Germany: increased incidence and urbanization of the disease?

No SARS-CoV-2 detection in the German CAPNETZ cohort of community acquired pneumonia before COVID-19 peak in March 2020

Recurrence of COVID-19 after recovery: a case report from Italy